结直肠癌中SP1的瘤内异质性表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2024.0212

摘要/Abstract

摘要： 目的探讨结直肠癌(colorectal cancer, CRC)中特异蛋白1(specificity protein 1, SP1)表达的瘤内异质性(intratumor heterogeneity, ITH)及其临床意义。方法收集CRC临床标本,采用免疫组化EnVision法检测SP1蛋白的表达水平及模式,明确SP1蛋白表达的ITH特征,定义SP1蛋白的ITH水平,并分析SP1蛋白ITH水平与CRC患者临床病理特征及预后的关系。结果在CRC中SP1蛋白呈典型的ITH表达特征,其ITH水平与淋巴结转移(P<0.001)和TNM分期(P<0.001)相关。生存分析表明,SP1蛋白高ITH患者的总生存期(overall survival, OS)显著低于SP1蛋白低ITH患者(61.25% vs 81.82%),差异有统计学意义(P=0.004)。单因素和多因素Cox回归分析显示,SP1蛋白高ITH是CRC患者不良OS(HR=2.680,P=0.017)的独立预测因子。结论 CRC中SP1蛋白的表达具有显著的ITH特征,并首次定义了SP1 ITH水平的量化标准,证实SP1蛋白高ITH与CRC进展及不良预后显著相关。

关键词: 结直肠癌, SP1蛋白, 瘤内异质性, 免疫组织化学, 预后

Abstract: Objective To investigate the intratumor heterogeneity(ITH)of specificity protein 1(SP1)protein expression in colorectal cancer(CRC)and its clinical significance. Methods Clinical specimens of CRC were collected. The expression level and pattern of SP1 protein were detected by immunohistochemical EnVision method. The ITH characteristics of SP1 protein expression were identified, and the ITH level of SP1 protein was defined. The relationship between ITH level of SP1 protein and clinicopathological characteristics and prognosis of CRC patients was analyzed. Results SP1 protein showed typical ITH expression in CRC. The ITH level of SP1 protein was associated with lymph node metastasis(P<0.001)and TNM stage(P<0.001). Survival analysis showed that the overall survival(OS)of patients with high ITH level of SP1 protein was significantly lower than that with low ITH level(61.25% vs 81.82%, P=0.004). Univariate and multivariate Cox regression analyses showed that high SP1 protein ITH was an independent predictor of poor OS in CRC patients(HR=2.680, P=0.017). Conclusion The expression of SP1 protein in CRC has significant ITH characteristics, and defines the quantitative criteria of SP1 ITH level for the first time. It is demonstrated that a high ITH level of SP1 protein is significantly associated with CRC progression and poor prognosis.

Key words: Colorectal cancer, SP1 protein, Intratumor heterogeneity, Immunohistochemistry, Prognosis

中图分类号:

R735.3

魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.

WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance[J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.

参考文献

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2] Lu Z, Chen Y, Liu D, et al. The landscape of cancer research and cancer care in China [J]. Nat Med, 2023, 29(12): 3022-3032.
[3] Du L, Cheng Q, Zheng H, et al. Targeting stemness of cancer stem cells to fight colorectal cancers [J]. Semin Cancer Biol, 2022, 82: 150-161. doi: 10.1016/j.semcancer.
[4] Jiang M, Jin S, Han J, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer [J]. Biomark Res, 2021, 9(1): 85. doi: 10.1186/s40364-021-00326-4.
[5] Pietropaolo G, Scarno G, Stabile H, et al. NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data [J]. Mol Aspects Med, 2021, 80: 100967. doi: 10.1016/j.mam.2021.100967.
[6] Crucitta S, Cucchiara F, Mathijssen R, et al. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours [J]. Cancer Treat Rev, 2022, 104: 102340. doi: 10.1016/j.ctrv.2022.102340.
[7] Mauri G, Vitiello PP, Sogari A, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer [J]. Br J Cancer, 2022, 127(3): 394-407.
[8] Al Zein M, Boukhdoud M, Shammaa H, et al. Immunotherapy and immunoevasion of colorectal cancer [J]. Drug Discov Today, 2023, 28(9): 103669. doi: 10.1016/j.drudis.2023.103669.
[9] Zhang GP, Xie ZL, Jiang J, et al. Mechanical confinement promotes heat resistance of hepatocellular carcinoma via SP1/IL4I1/AHR axis [J]. Cell Rep Med, 2023, 4(8): 101128. doi: 10.1016/j.xcrm.2023.101128.
[10] Zhang M, Kan D, Zhang B, et al. P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC [J]. J Exp Clin Cancer Res, 2023, 42(1): 215. doi: 10.1186/s13046-023-02777-z.
[11] Zhao G, Yuan H, Li Q, et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2 [J]. Signal Transduct Target Ther, 2022, 7(1): 275. doi: 10.1038/s41392-022-01096-7.
[12] Zhu Z, Guo Y, Liu Y, et al. ELK4 Promotes colorectal cancer progression by activating the neoangiogenic factor LRG1 in a noncanonical SP1/3-dependent manner [J]. Adv Sci(Weinh), 2023, 10(32): e2303378. doi: 10.1002/advs.202303378.
[13] Fosso E, Leo M, Muccillo L, et al. Quercetins dual mode of action to counteract the Sp1-miR-27a axis in colorectal cancer cells [J]. Antioxidants(Basel), 2023, 12(8): 1547. doi: 10.3390/antiox12081547.
[14] Tang T, Fang D, Ji Z, et al. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells [J]. Cell Oncol(Dordr), 2023. doi: 10.1007/s13402-023-00887-6.
[15] Liu J, Zhan W, Chen G, et al. SP1-induced PROX1-AS1 contributes to tumor progression by regulating miR-326/FBXL20 axis in colorectal cancer [J]. Cell Signal, 2023, 101: 110503. doi: 10.1016/j.cellsig.2022.110503.
[16] Kahn AM, Golestani R, Harigopal M, et al. Intratumor spatial heterogeneity in programmed death-ligand 1(PD-L1)protein expression in early-stage breast cancer [J]. Breast Cancer Res Treat, 2023, 201(2): 289-298.
[17] Ge LP, Jin X, Ma D, et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer [J]. Cell Res, 2024, 34(1): 58-75.
[18] Geng K, Merino LG, Veiga RG, et al. Intrinsic deletion at 10q23.31, including the PTEN gene locus, is aggravated upon CRISPR-Cas9-mediated genome engineering in HAP1 cells mimicking cancer profiles [J]. Life Sci Alliance, 2023, 7(2): e202302128. doi: 10.26508/lsa.202302128.
[19] Tornesello ML, Cerasuolo A, Starita N, et al. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations [J]. Front Cell Dev Biol, 2023, 11: 1286683. doi: 10.3389/fcell.2023.1286683.
[20] Enikeeva K, Rafikova G, Sharifyanova Y, et al. Epigenetics as a key factor in prostate cancer [J]. Adv Biol(Weinh), 2024, 20: e2300520. doi: 10.1002/adbi.202300520.
[21] Gasperoni JG, Fuller JN, Darido C, et al. Grainyhead-like(Grhl)target genes in development and cancer [J]. Int J Mol Sci, 2022, 23(5): 2735. doi: 10.3390/ijms23052735.
[22] He W, Hong X, Chen G, et al. RNA modifications in gynecological cancer: current status and future directions [J]. Front Med(Lausanne), 2024, 11: 1314075. doi: 10.3389/fmed.2024.1314075.
[23] Su X, Lu R, Qu Y, et al. Diagnostic and therapeutic potentials of methyltransferase-like 3 in liver diseases [J]. Biomed Pharmacother, 2024, 172: 116157. doi: 10.1016/j.biopha.2024.116157.
[24] Peng N, Liu J, Hai S, et al. Role of post-translational modifications in colorectal cancer metastasis [J]. Cancers(Basel), 2024, 16(3): 652. doi: 10.3390/cancers16030652.
[25] Taylor BC, Sun X, Gonzalez-Ericsson PI, et al. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple negative breast cancer [J]. Cancer Discov, 2024, 14(2): 290-307.
[26] Corpetti M, Müller C, Beltran H, et al. Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes [J]. Eur Urol, 2024, 85(3): 193-204.
[27] Wang Y, Zhou Y, Yang L, et al. Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy [J]. Adv Sci(Weinh), 2024, 11(1): e2303175. doi: 10.1002/advs.202303175.
[28] Valenza C, Guidi L, Battaiotto E, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers [J]. Trends Cancer, 2024, 10(2): 113-123.

相关文章 15

[1]	黄方康瑞吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[2]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[3]	吴霖,石晨曦,童星. 肺良性转移性平滑肌瘤病7例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(4): 78-84.
[4]	杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[5]	刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[6]	董雅琪,王新慧,赵颖慧,王传新. 血清外泌体LINC02163作为结直肠癌远处转移标志物的临床价值[J]. 山东大学学报 (医学版), 2023, 61(9): 19-28.
[7]	宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[8]	樊荣,李彬彬,马晓丽,汪运山,郏雁飞. 胃癌中DEC2、HIF-2α的表达及临床意义[J]. 山东大学学报 (医学版), 2023, 61(7): 12-18.
[9]	刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.
[10]	胡立勇,钟浩,房娟娟,国巍,张雨露,范医东. 基于数据库分析CCR基因对肾透明细胞癌预后的预测价值[J]. 山东大学学报 (医学版), 2023, 61(4): 49-55.
[11]	李兆辉,李亮,周飞,郑超,周文重,王斐,余之刚. 乳腺炎性肌纤维母细胞瘤1例及文献回顾[J]. 山东大学学报 (医学版), 2023, 61(4): 121-124.
[12]	陈蓉,杨越,杨智翔,苏亚英,庞智英,王大伟,崔书君,杨飞. 基于CT纹理分析预测急性肺栓塞短期预后[J]. 山东大学学报 (医学版), 2023, 61(12): 78-85.
[13]	华月帆,何珂瑶,张家豪,钱梦凡,刘怡文,孔金玉,杨海军,周福有. 具核梭杆菌诱导缺氧诱导因子及血管生成因子高表达对食管鳞癌患者生存预后的影响[J]. 山东大学学报 (医学版), 2023, 61(11): 59-67.
[14]	赵启迪,王凯,赵小刚,闫涛,王亚东,杜贾军. 基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型[J]. 山东大学学报 (医学版), 2023, 61(10): 23-37.
[15]	郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed